US Edition
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
- Nektar Therapeutics revealed it will webcast its involvement in the H.C. Wainwright BioConnect Investor Conference, scheduled for May 20, 2025, in New York City.
- This event follows Nektar's May 13, 2025 announcement of its clinical-stage programs targeting immunological dysfunction in autoimmune and inflammatory diseases.
- The webcast will begin at 1:30 p.m. Eastern Time from the Nasdaq Headquarters and will be accessible via Nektar’s Investor Events website with a 30-day replay.
- Nektar’s lead candidate, rezpegaldesleukin , a regulatory T cell stimulator, is in two Phase 2b trials for atopic dermatitis and alopecia areata.
- Nektar’s pipeline also includes preclinical and clinical-stage assets like TNFR2 antibodies, bispecific programs, and the immune-boosting IL-15 receptor agonist NKTR-255.
Insights by Ground AI
Does this summary seem wrong?
27 Articles
27 Articles
All
Left
1
Center
14
Right
Helena Independent Record+25 Reposted by 25 other sources
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City…
·Helena, United States
Read Full Article
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that…
Coverage Details
Total News Sources27
Leaning Left1Leaning Right0Center14Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
